A real-world study of dosing patterns in patients with spinal muscular atrophy (SMA) type 1 treated with nusinersen in the United States
Latest Information Update: 11 Jun 2021
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- 11 Jun 2021 New trial record
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology